Primary sjögren's syndrome among patients with cerebral infarction

To investigate the clinical features, treatment, and outcomes in cerebral infarction (CI) patients with Sjögrens syndrome (pSS) for novel disease management strategies. A total of 27 patients diagnosed with CI with pSS were divided into the treatment group (12 patients) and non-treatment group (15 patients) according to whether they were treated for pSS in the acute and secondary prevention stage of CI. The related clinicopathological information including age, gender, medical history, experimental data, clinical manifestations, imaging data, treatment, functional recovery and recurrences were retrospectively analyzed. The clinical manifestations of 27 CI patients with pSS varied widely. There were also no significant differences in age, gender, traditional high-risk factors of CI, previous history, experimental data, and short-term nerve functional recovery between the two groups (p > 0.05). After 1 year of treatment, timely treatment of pSS can significantly improve the prognosis, the favorable prognosis (modified Rankin scale ≤ 2) of the treatment and non-treatment groups were 83.3% and 40.0% respectively. The recurrence rate of CI was 0% in the treatment group but 33.3% in the non-treatment group. Compared to the no treatment group. The odds of achieving a favorable prognosis in the treatment group were 7.5 times higher than in the non-treatment group (OR = 7.5, 95% CI: 1.195-47.1). the adjusted odds ratio was 0.113 (95% CI: 0.002-1.214). This indicates an 89% reduction in recurrence odds with treatment. PSS screening is necessary for CI patients. Moreover, prompt pSS treatment administered during the acute and secondary prevention stage of CI with pSS can promote neurologic functional independence and reduce the risk of CI recurrent.